ACTH Lab: "Normal" vs Functional Optimal Range Explained

What ACTH Is and Why Clinicians Measure It

Adrenocorticotropic hormone (ACTH) is a 39-amino-acid peptide released by corticotroph cells in the anterior pituitary in response to hypothalamic corticotropin-releasing hormone (CRH). Its primary job is to stimulate the adrenal cortex to produce cortisol, aldosterone precursors, and adrenal androgens like DHEA-S. Measuring plasma ACTH alongside serum cortisol lets clinicians pinpoint whether a dysfunction originates in the adrenal glands, the pituitary, or the hypothalamus. The Endocrine Society's 2016 Clinical Practice Guideline on adrenal insufficiency identifies the ACTH level as the first branch-point in distinguishing primary from secondary disease.

The Hypothalamic-Pituitary-Adrenal Axis in Brief

CRH from the hypothalamus drives pituitary ACTH secretion. ACTH then drives adrenal cortisol output. Cortisol feeds back negatively on both the hypothalamus and pituitary to suppress further ACTH release. When any part of this loop fails, ACTH either climbs or falls in predictable ways that a single well-timed blood draw can expose.

Why Timing and Collection Matter

ACTH degrades rapidly at room temperature. A sample left unspun for 30 minutes can lose 30 to 50% of measurable peptide before analysis even begins. The draw must occur between 7 and 9 AM, collected into a pre-chilled EDTA (purple-top) tube, placed on ice immediately, spun within 15 minutes, and the plasma frozen until assay. A 2019 technical note in the Annals of Clinical Biochemistry confirmed that delayed centrifugation is one of the most common causes of spuriously low ACTH results in outpatient settings.

The Standard Reference Range vs Functional Optimal

The standard lab range printed on most reports reads 6 to 50 pg/mL for a morning draw, though exact cutoffs vary by assay platform. Quest Diagnostics uses 7.2 to 63.3 pg/mL; LabCorp uses 6 to 50 pg/mL. Both are assay-calibration ranges rather than health-outcome-derived thresholds.

Where "Normal" Comes From

Reference ranges are built from the middle 95% of a presumably healthy population. That construction means 2.5% of truly healthy adults fall below the lower limit and 2.5% fall above the upper limit by definition. Ranges also do not account for diurnal phase, pre-analytical handling errors, or the difference between a person who is subclinically stressed during the draw and one who is fully rested.

The Functional Optimal Window

Clinicians who interpret ACTH in the context of whole-axis function typically target 10 to 35 pg/mL on a morning draw, with cortisol simultaneously in the 15 to 25 mcg/dL range. This narrower target is not an arbitrary preference. A study published in the Journal of Clinical Endocrinology and Metabolism (JCEM) in 2014 demonstrated that patients with morning cortisol below 5 mcg/dL paired with ACTH below 10 pg/mL had a high probability of secondary adrenal insufficiency on formal stimulation testing, while those with cortisol above 18 mcg/dL were highly unlikely to fail the stimulation test regardless of ACTH value.

The table below summarizes the three-zone interpretation framework used by HealthRX clinicians during HPA-axis workup.

| Zone | Morning ACTH | Morning Cortisol | Interpretation | |---|---|---|---| | Optimal | 10 to 35 pg/mL | 15 to 25 mcg/dL | HPA axis likely intact | | Gray zone | 5 to 10 or 35 to 50 pg/mL | 5 to 18 mcg/dL | Stimulation testing indicated | | Pathologic concern | <5 or >50 pg/mL | <5 or >20 mcg/dL | Formal endocrine evaluation required |

Why the Gap Between "Normal" and "Optimal" Matters Clinically

A patient with ACTH of 8 pg/mL sits inside the standard reference range. That same patient may have secondary adrenal insufficiency. The Endocrine Society guideline states: "A morning plasma cortisol concentration of less than 5 mcg/dL is highly suggestive of adrenal insufficiency, whereas a value greater than 18 mcg/dL effectively rules it out." ACTH below 10 pg/mL in that low-cortisol context points the finger squarely at the pituitary or hypothalamus, not the adrenal gland.

What High ACTH Means

A morning ACTH consistently above 50 pg/mL, confirmed on repeat testing with verified pre-analytical technique, narrows the differential to three main categories.

Primary Adrenal Insufficiency (Addison Disease)

When the adrenal cortex cannot produce adequate cortisol, negative feedback on the pituitary is lost and ACTH rises, sometimes dramatically. Values above 200 pg/mL are common in established Addison disease. A 2021 review in the New England Journal of Medicine described classic Addison disease as presenting with ACTH levels frequently exceeding 300 pg/mL alongside cortisol values below 3 mcg/dL. Autoimmune destruction of the adrenal cortex accounts for roughly 80 to 90% of primary adrenal insufficiency cases in high-income countries.

Cushing Disease (Pituitary ACTH Excess)

A pituitary corticotroph adenoma drives autonomous ACTH overproduction. Unlike primary adrenal insufficiency, cortisol is also high. Morning ACTH in Cushing disease typically ranges from 50 to 200 pg/mL. The 2021 Endocrine Society Clinical Practice Guideline on Cushing syndrome specifies that a 24-hour urinary free cortisol above 4 times the upper limit of normal alongside elevated ACTH strongly suggests a pituitary or ectopic source rather than primary adrenal overproduction. The guideline is available on PubMed here.

Ectopic ACTH Syndrome

Small-cell lung carcinoma, carcinoid tumors, and pancreatic neuroendocrine tumors can secrete ACTH independently of pituitary control. ACTH values in ectopic syndrome are often markedly elevated, sometimes above 500 pg/mL, with corresponding severe hypercortisolism, hypokalemia, and rapid-onset muscle wasting. A large case series published in JCEM found median ACTH in confirmed ectopic ACTH syndrome was 348 pg/mL, compared with 96 pg/mL in pituitary-dependent Cushing disease.

What Low ACTH Means

Low ACTH, defined here as below 10 pg/mL on a verified morning draw, combined with low cortisol, points to a problem upstream of the adrenal gland.

Secondary Adrenal Insufficiency

Pituitary disease, whether from a non-functioning adenoma, pituitary surgery, cranial irradiation, or traumatic brain injury, reduces corticotroph cell mass or function. ACTH output falls, the adrenal cortex atrophies from disuse, and cortisol production drops. A 2016 meta-analysis in the European Journal of Endocrinology found secondary adrenal insufficiency affected approximately 25 to 35% of patients in the first year after pituitary surgery.

Tertiary Adrenal Insufficiency and Exogenous Steroid Suppression

Long-term glucocorticoid therapy, including prednisone at doses as low as 5 mg/day for more than 4 weeks, suppresses hypothalamic CRH secretion. ACTH falls, the adrenals shrink, and abrupt steroid discontinuation can precipitate adrenal crisis. A 2020 paper in the BMJ estimated that up to 2 million Americans may have some degree of HPA suppression from prescribed glucocorticoids at any given time. Inhaled corticosteroids at high doses (fluticasone 500 mcg/day or more) also cause measurable ACTH suppression in a subset of patients.

Low ACTH in the Context of Normal Cortisol

A low ACTH with a simultaneously normal or high cortisol raises the possibility of a primary cortisol-secreting adrenal adenoma. In that scenario, autonomous adrenal cortisol output suppresses pituitary ACTH via negative feedback. This pattern appears in subclinical Cushing syndrome, which a 2017 JCEM consensus statement estimated affects 1.6 to 2.4% of patients with incidentally discovered adrenal nodules on cross-sectional imaging.

The Cosyntropin Stimulation Test: When ACTH Alone Is Not Enough

A single baseline ACTH measurement cannot confirm adrenal insufficiency by itself. The standard diagnostic test is the 250 mcg intravenous or intramuscular cosyntropin (synthetic ACTH 1-24, brand name Cortrosyn) stimulation test. Cortisol is measured at 0, 30, and 60 minutes. A peak cortisol below 18 mcg/dL is the widely used threshold for an abnormal (insufficient) response, though the Endocrine Society guideline notes that cutoffs vary by assay and some centers use 500 nmol/L (roughly 18.1 mcg/dL) as the threshold. A 1 mcg low-dose cosyntropin test may detect milder secondary insufficiency, but that protocol is not yet universally standardized.

Interpreting the Stimulation Test Alongside Baseline ACTH

Pairing baseline ACTH with the stimulation result tells the full story. High baseline ACTH plus blunted stimulation response confirms primary adrenal insufficiency. Low baseline ACTH plus blunted stimulation response confirms secondary or tertiary insufficiency. Normal ACTH plus blunted stimulation in a patient on inhaled or intranasal steroids suggests partial HPA suppression from exogenous glucocorticoids. A 2018 paper in the Annals of Internal Medicine argued that the stimulation test remains the most practical single test for outpatient adrenal insufficiency screening, with sensitivity of approximately 97% for primary disease.

How to Approach an Abnormal ACTH Result

The right next step depends on whether ACTH is high or low and what cortisol is doing simultaneously.

When ACTH Is High

An ACTH above 50 pg/mL should trigger a simultaneous morning cortisol. If cortisol is low (below 10 mcg/dL), arrange cosyntropin stimulation and measure adrenal antibodies (21-hydroxylase antibodies) to screen for autoimmune Addison disease. If cortisol is also elevated, order a 24-hour urinary free cortisol, a late-night salivary cortisol on two separate evenings, and a 1 mg overnight dexamethasone suppression test to evaluate for Cushing syndrome. Pituitary MRI follows if the biochemistry confirms ACTH-dependent hypercortisolism. The Endocrine Society Cushing guideline recommends at least two first-line tests positive before pursuing imaging, because false-positive rates for individual tests range from 5 to 15%.

When ACTH Is Low

An ACTH below 10 pg/mL with a low morning cortisol should prompt a detailed medication history, specifically looking for any exogenous glucocorticoid exposure in the past 6 to 12 months. If no exogenous source is identified, pituitary MRI and a full anterior pituitary hormone panel (TSH, free T4, IGF-1, LH, FSH, prolactin) are the next step. A 2022 review in the Journal of Clinical Endocrinology and Metabolism noted that hypopituitarism is under-diagnosed in patients who received cranial radiation more than 10 years prior, with ACTH deficiency developing in up to 45% at 10-year follow-up.

Lifestyle and Medication Factors That Shift ACTH

Several non-pathologic factors alter ACTH readings and must be considered before labeling a result abnormal. Acute physical or psychological stress raises ACTH within minutes through the CRH pathway. A 2019 study in Psychoneuroendocrinology documented ACTH increases of 40 to 80% above baseline within 10 minutes of a standardized psychological stressor in healthy adults. Megestrol acetate (a progesterone analogue used in oncology), high-dose medroxyprogesterone, and depot forms of progestin-only contraception all have glucocorticoid-like activity sufficient to suppress ACTH. Opioid therapy at any dose suppresses CRH secretion and can drive ACTH below 10 pg/mL in chronic users.

ACTH in Hormone Therapy Contexts

Patients pursuing testosterone replacement therapy (TRT), hormone replacement therapy (HRT), or GLP-1 receptor agonist programs may have ACTH drawn as part of a broader adrenal panel. Testosterone itself does not directly suppress ACTH, but the stress of undertreated hypogonadism may chronically activate the HPA axis. A small 2020 crossover trial in Andrology found that men with untreated late-onset hypogonadism had slightly elevated morning ACTH values that normalized after 12 weeks of testosterone undecanoate 1,000 mg IM. Estradiol, at physiologic concentrations, modestly upregulates CRH receptor sensitivity, which may explain why some women report worsening fatigue and stress intolerance when estradiol is suboptimal during perimenopause. A 2019 review in Frontiers in Endocrinology explored the bidirectional relationship between gonadal steroids and HPA-axis tone.

GLP-1 Agonists and Adrenal Function

Semaglutide and tirzepatide have not been shown to directly alter ACTH or cortisol in humans at therapeutic doses. Patients who lose significant weight on GLP-1 therapy (STEP-1 [N=1,961] reported 14.9% mean body weight loss at 68 weeks with semaglutide 2.4 mg vs. 2.4% with placebo) as published in the New England Journal of Medicine may have reduced HPA-axis tone over time, because adipose tissue itself is a site of cortisol regeneration via 11-beta-hydroxysteroid dehydrogenase type 1 activity. Clinicians should not expect GLP-1 therapy to produce dramatic ACTH shifts, but patients with pre-existing subclinical adrenal insufficiency may feel the effect of caloric restriction more acutely during the dose-escalation phase.

How to Raise ACTH (If It Is Pathologically Low)

The answer depends entirely on the cause.

Secondary Insufficiency from Pituitary Disease

There is no approved medication that directly stimulates pituitary ACTH secretion in clinical practice outside of diagnostic testing. Treatment is cortisol replacement, typically hydrocortisone 15 to 25 mg/day divided into two or three doses that mimic the diurnal cortisol curve. The Endocrine Society guideline recommends hydrocortisone as first-line replacement over prednisone for secondary adrenal insufficiency because its shorter half-life more closely mirrors endogenous secretion patterns.

HPA Suppression from Exogenous Glucocorticoids

Gradual tapering of the offending steroid over weeks to months allows the hypothalamic-pituitary axis to recover. A tapering schedule should not be rushed; a practical review in the BMJ suggested reducing the prednisone-equivalent dose by no more than 10% every 1 to 2 weeks once the dose is below physiologic replacement range (7.5 mg/day prednisone equivalent).

How to Lower ACTH (If It Is Pathologically High)

Elevated ACTH from primary adrenal insufficiency is corrected by replacing cortisol. The adrenal gland's failure to produce cortisol is the driver of the elevated ACTH, so adequate hydrocortisone or fludrocortisone replacement restores negative feedback and brings ACTH back toward the normal range over days to weeks.

Elevated ACTH from Cushing disease requires targeting the pituitary adenoma. First-line treatment is transsphenoidal surgery. A 2015 Cochrane review found remission rates of 65 to 90% after initial pituitary surgery for Cushing disease, with ACTH normalizing in parallel with cortisol. Second-line medical therapies include pasireotide (a somatostatin receptor agonist that reduces ACTH secretion from corticotroph adenomas), osilodrostat (an 11-beta-hydroxylase inhibitor), and cabergoline (a dopamine agonist with modest efficacy in around 30 to 40% of patients). The FDA approval for pasireotide specified its indication as Cushing disease in adults for whom surgery was not an option or had failed.